A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for acute myeloid leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5.

Trial Profile

A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for acute myeloid leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin; Etoposide
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AML-LEN5
  • Most Recent Events

    • 31 May 2012 Additional trial location (Scotland) identified as reported by UKCRN.
    • 24 Mar 2012 Planned number of patients changed from 39 to 47 as reported by European Clinical Trials Database record.
    • 03 Dec 2010 Planned End Date changed from 1 Mar 2010 to 20 Oct 2010 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top